Rigel Pharmaceuticals Inc (RIGL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $837.18M
Last updated: Nov 17, 2026 at 11:06 AM ET
Rigel Pharmaceuticals Inc (RIGL) Stock Forecast
Analysts expect Rigel Pharmaceuticals (RIGL) to earn $3.34 per share in the fiscal year ending Dec 31, 2026, on revenue of $306.34M. Of 5 analysts, 3 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.40, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 60% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 3 | 60.0% |
| Hold | 2 | 40.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 43.1% and revenue estimates rise 22.2%.
- Fiscal year ending Dec 31, 2026
- $3.34
- EPS consensus, revenue $306.34M
- Fiscal year ending Dec 31, 2027
- $4.78
- EPS consensus, revenue $374.43M
- Next report
- Mar 1, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $3.34 | $2.84 to $4.58 | 4 | $306.34M | $294.06M to $311.72M | 5 |
| Dec 31, 2027 | $4.78 | $2.80 to $7.07 | 4 | $374.43M | $330.00M to $410.10M | 5 |
Quarterly Estimates
The EPS consensus falls from $0.94 for the quarter ending Dec 31, 2026 to $0.52 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.94 | $0.85 to $1.06 | 7 | $93.37M | $85.26M to $98.39M | 7 |
| Mar 31, 2027 | $0.52 | $0.52 to $0.52 | 1 | $77.80M | $70.00M to $85.60M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 3 |
| Fiscal year ending Dec 31, 2027 | 2 | 2 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 2.6% from $3.43.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $3.34 | $3.54 | $3.54 | $3.54 | $3.43 | -2.7% |
| Fiscal year ending Dec 31, 2027 | $4.78 | $4.94 | $4.94 | $4.94 | $4.39 | +8.7% |
| Quarter ending Mar 31, 2027 | $0.52 | $0.57 | $0.57 | $0.57 | $0.57 | -8.8% |
Frequently Asked Questions About RIGL
What is the RIGL stock forecast?
Consensus analyst estimates put Rigel Pharmaceuticals's EPS at $3.34 for the fiscal year ending Dec 31, 2026, on revenue of $306.34M. The consensus rating from 5 analysts is Buy.
How do analysts rate RIGL stock?
Of 5 analysts covering Rigel Pharmaceuticals, 0 rate it Strong Buy, 3 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from RIGL next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.34, with estimates from $2.84 to $4.58 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $4.78, with estimates from $2.80 to $7.07 from 4 analysts.
What revenue do analysts expect from Rigel Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $306.34M, with estimates from $294.06M to $311.72M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $374.43M, with estimates from $330.00M to $410.10M.
How many analysts cover RIGL?
5 analysts rate Rigel Pharmaceuticals stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
RIGL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors